- $116.26m
- $145.26m
- $94.64m
- 39
- 62
- 72
- 59
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.98 | ||
| Price to Tang. Book | 7.58 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.23 | ||
| EV to EBITDA | 27.23 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.45% | ||
| Return on Equity | -22.4% | ||
| Operating Margin | -3.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 99.22 | 66.5 | 75.36 | 90.21 | 94.64 | 94.92 | 101.41 | 4.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization (CDMO). The Company is engaged in spanning pre-investigational new drug development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a primary focus in the area of small molecules. It is a CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company's key products include Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR and Donnatal liquids and tablets. Its manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms, with specialization in modified release technologies and facilities to handle potent compounds and controlled substances.
Directors
- Wayne Weisman CHM (65)
- J. David Enloe PRE (57)
- Ryan Lake CFO (43)
- William Ashton IND (70)
- Michael Berelowitz IND (76)
- Winston Churchill IND (80)
- James Miller IND (70)
- Laura Parks IND (62)
- Bryan Reasons IND (53)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 15th, 2007
- Public Since
- March 7th, 2014
- No. of Shareholders
- 6
- No. of Employees
- 258
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 105,690,922
- Address
- 1 E. UWCHLAN AVE, SUITE 112, EXTON, 19341
- Web
- https://www.societalcdmo.com/
- Phone
- +1 7705348239
- Contact
- Stephanie Diaz
- Auditors
- KPMG LLP
Upcoming Events for SCTL
Societal CDMO Inc Annual Shareholders Meeting
Q2 2024 Societal CDMO Inc Earnings Release
Similar to SCTL
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
FAQ
What is the Societal CDMO share price?
As of Today at 19:20 UTC, shares in Societal CDMO are trading at $1.10. This share price information is delayed by 15 minutes.
How has the Societal CDMO share price performed this year?
Shares in Societal CDMO last closed at $1.10 and the price had moved by +2.8% over the past 365 days. In terms of relative price strength the Societal CDMO share price has underperformed the S&P500 Index by -18.83% over the past year.
What are the analyst and broker recommendations for Societal CDMO?
The overall consensus recommendation for Societal CDMO is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Societal CDMO dividend yield?
Societal CDMO does not currently pay a dividend.
Does Societal CDMO pay a dividend?
Societal CDMO does not currently pay a dividend.
When does Societal CDMO next pay dividends?
Societal CDMO does not currently pay a dividend.
How do I buy Societal CDMO shares?
To buy shares in Societal CDMO you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Societal CDMO?
As of the previous close price of $1.10, shares in Societal CDMO had a market capitalisation of $116.26m.
Where are Societal CDMO shares listed?
Here are the trading details for Societal CDMO:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SCTL
What kind of share is Societal CDMO?
Based on an overall assessment of its quality, value and momentum Societal CDMO is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Societal CDMO share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Societal CDMO share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Societal CDMO. Over the past six months, its share price has outperformed the S&P500 Index by +108.27%.
As of the last closing price of $1.10, shares in Societal CDMO were trading +81.69% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Societal CDMO PE Ratio?
The Societal CDMO PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Societal CDMO?
Societal CDMO's management team is headed by:
- Wayne Weisman - CHM
- J. David Enloe - PRE
- Ryan Lake - CFO
- William Ashton - IND
- Michael Berelowitz - IND
- Winston Churchill - IND
- James Miller - IND
- Laura Parks - IND
- Bryan Reasons - IND